Fast vs. Slow Switching from Stimulants to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

被引:3
作者
Cardo, Esther [1 ]
Porsdal, Vibeke
Quail, Deborah [2 ]
Fuentes, Joaquin [3 ]
Steer, Christopher [4 ]
Montoya, Alonso [5 ]
Anand, Ernie [6 ]
Escobar, Rodrigo [7 ]
机构
[1] Son Llatzer Univ Balearic Isl, Neuropediat Hosp, Univ Inst Res Healthcare Sci, Dept Neuropediat, E-07198 Palma De Mallorca, Spain
[2] Lilly UK, European Stat, Windlesham, Surrey, England
[3] Policlin Gipuzkoa, San Sebastian 20009, Spain
[4] Victoria Hosp, Dept Paediat, Kirkcaldy, Fife, Scotland
[5] Lilly Labs Spain, Dept Med, Alcobendas, Spain
[6] Neurosci Med Affairs EU, Windlesham, Surrey, England
[7] Lilly Res Labs Japan, Med Sci, Neurosci Prod, Chuo Ku, Kobe, Hyogo, Japan
关键词
DEFICIT HYPERACTIVITY DISORDER; BLOOD-PRESSURE; METHYLPHENIDATE; AMPHETAMINE; EFFICACY; VALIDITY;
D O I
10.1089/cap.2012.0027
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: To compare fast versus slow switching from stimulants to atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods: This was a randomized, controlled, open-label study in 6-16-year-old ADHD patients, previously treated with stimulants and cross-titrated (fast switch, over 2 weeks, or slow switch, over 10 weeks) to ATX because of unsatisfactory response and/or adverse events. Study duration was 14 weeks with an ATX standard target dose of 1.2 mg/kg/day. Primary measure was the change from baseline in the investigator-rated ADHD-Rating Scale (ADHD-RS) at weeks 2 and 10. Secondary measures included Global Impression of Perceived Difficulties (GIPD) and Child Health and Illness Profile-Child Edition (CHIP-CE). Results: The majority of the 111 patients were male (83.8%, n = 93) and mean (SD) age was 11.5 (2.38) years. Mean baseline ADHD-RS total score was 36.0 in the fast and 38.0 in the slow group. Adjusted mean change after 2 weeks was -8.1 (-10.1; -6.1) in the fast and -8.0 (-9.9; -6.0) in the slow group (p = 0.927), and after 10 weeks -15.0 (-17.4; -12.6) and -14.3 (-16.7; -12.0), respectively, (p = 0.692). GIPD scores did not show differences between groups. Significant differences at week 10 were found in the CHIP-CE achievement domain favoring slow (p = 0.036) and the comfort domain favoring fast cross-titration (p = 0.030). No significant differences were found for adverse events, and differences for systolic blood pressure (BP) and weight were not considered clinically relevant. Conclusions: ADHD-RS and GIPD scores improved in both switching groups. No clinically relevant differences between fast and slow switching from stimulants to ATX were found.
引用
收藏
页码:252 / 261
页数:10
相关论文
共 23 条
[1]   Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): Efficacy rate and side effects [J].
Ahmann, PA ;
Theye, FW ;
Berg, R ;
Linquist, AJ ;
Van Erem, AJ ;
Campbell, LR .
PEDIATRICS, 2001, 107 (01) :E10
[2]  
[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
[3]   A pilot study for augmenting atomoxetine with methylphenidate: Safety of concomitant therapy in children with attention-deficit/hyperactivity disorder [J].
Carlson G.A. ;
Dunn D. ;
Kelsey D. ;
Ruff D. ;
Ball S. ;
Ahrbecker L. ;
Allen A.J. .
Child and Adolescent Psychiatry and Mental Health, 1 (1)
[4]   High blood pressure trends in children and adolescents in national surveys, 1963 to 2002 [J].
Din-Dzietham, Rebecca ;
Liu, Yong ;
Bielo, Marie-Vero ;
Shamsa, Falah .
CIRCULATION, 2007, 116 (13) :1488-1496
[5]  
DuPaul GJ, 1998, ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation
[6]   Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial [J].
Efron, D ;
Jarman, F ;
Barker, M .
PEDIATRICS, 1997, 100 (04) :662-666
[7]  
European Medicines Agency (EMA), PHARM WORK PART PHVW
[8]   Stimulant medications [J].
Greenhill, LL ;
Halperin, JM ;
Abikoff, H .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1999, 38 (05) :503-512
[9]  
Guy W., 1976, ECDEU Assessment Manual for Psychopharmacology, P218
[10]   Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime version (K-SADS-PL): Initial reliability and validity data [J].
Kaufman, J ;
Birmaher, B ;
Brent, D ;
Rao, U ;
Flynn, C ;
Moreci, P ;
Williamson, D ;
Ryan, N .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1997, 36 (07) :980-988